rs10502901 - ACAA2

Magnitude 2.0 · 1 study on file

Reported associations

• A Prospective Trial of Abiraterone Acetate Plus Prednisone in Black and White Men With Metastatic Castrate-Resistant Prostate Cancer - Unknown journal (n.d.) · Unknown authors · PubMed 33951180

  ABSTRACT: BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednisone to explore outcomes by race. METHODS: This race-stratified, multicenter study estimated radiographic progression-free survival (rPFS) in Black and White men with mCRPC. Secondary end points included prostate-specific antigen (PSA) kinetics, overall survival (OS), and safety. Exploratory analysis included genome-wide genotyping to identify single nucleotide polymorphisms associated with progression in a model incorporating genetic ancestry. One hundred patients self-identified as White (n = 50) or Black (n = 50) were enrolled.

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.